Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$151.04M+410.67%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Serge Saxonov
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,178
- Beta
- 1.99
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 25.83
Financials
Revenue
$151.04M+410.7%Net Income
$-17.93MEBITDA
$-8.98MFree Cash Flow
$15.39MEPS (diluted)
$-0.14Shares Outstanding (diluted)
129.98M+901.0%Operating Expenses
$135.45MCash & Debt
$552.03MRevenue by Segment (annual)
$1.24BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $642.82M | $-43.54M | $-0.35 |
| 2024 | $610.78M | $-182.63M | $-1.52 |
| 2023 | $618.73M | $-255.10M | $-2.18 |
| 2022 | $516.41M | $-166.00M | $-1.46 |
| 2021 | $490.49M | $-58.22M | $-0.53 |
| 2020 | $298.85M | $-542.73M | $-5.37 |
| 2019 | $245.89M | $-31.25M | $-0.80 |
| 2018 | $146.31M | $-112.48M | $-8.40 |
| 2017 | $71.08M | $-18.76M | $-1.62 |
Valuation
TXGhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (9)
- Newsprnewswire.com·6d ago·Neutral
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026 PLEASANTON, Calif., Oct. 13, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the third quarter ended September 30, 2026 after market close on Thursday, November 5, 2026.
View source ↗ - Newszacks.com·11d ago·Negative
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
View source ↗ - Newsprnewswire.com·12d ago·Negative
…ancer and a single cell approach to residual disease detection in acute myeloid leukemia PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a multi-project research collaboration with Fred Hutchinson Cancer Center (Fred Hutch), one of the nation's leading cancer research institutions, to advance the use of single cell and spatial technologies in both soli…
View source ↗ - Newsdefenseworld.net·15d ago·Positive
Torex Gold Targets Growth, C$350M Returns and Morelos Expansion Torex Gold Resources (TSE: TXG) outlined plans to build on production from its Morelos property in Mexico, advance the Los Reyes development project and return capital to shareholders as it seeks to close what it described as a valuation gap. During a company presentation, Andrew, a Torex speaker, said the company's strategy rests on "strong execution,
View source ↗ - Newszacks.com·19d ago·Positive
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its spatial biology platform.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
…rs to minutes, putting rapid, iterative analysis at the fingertips of every researcher PLEASANTON, Calif., Sept. 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced Sentira, a new cloud analysis platform that extends the 10x experience from data generation to experimental conclusions, beginning with Sentira Spatial Analysis.
View source ↗ - Newsdefenseworld.net·23d ago·Negative
10x Genomics (NASDAQ:TXG) Stock: Insider Shehnaaz Suliman Sells 5,723 Shares 10x Genomics (NASDAQ: TXG - Get Free Report) Director Shehnaaz Suliman sold 5,723 shares of the business's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $81.19, for a total transaction of $464,650.37. Following the transaction, the director directly owned 23,792 shares of the company's stock, valued at
View source ↗ - Newszacks.com·46d ago·Neutral
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.
View source ↗ - Newszacks.com·49d ago·Positive
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences 10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.
View source ↗
Earnings
Thu, Nov 5(in 2 weeks)
Consensus estimate $-0.26 per share
Typical surprise +31.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.14 vs $-0.24beat
- Thu, May 7$-0.10 vs $-0.29beat
- Thu, Feb 12$-0.13 vs $-0.19beat
- Thu, Nov 6$-0.22 vs $-0.07miss
- Thu, Aug 7$0.28 vs $-0.35beat
- Thu, May 8$-0.36 vs $-0.45beat
Estimates and results for TXG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TXG officers and directors.
- Bought
- $446k
- Sold
- $18.3m
1 trade
64 trades
- Suliman Shehnaazsold
- Suliman Shehnaazsold
- Suliman Shehnaazsold
- Suliman Shehnaazsold
- Suliman Shehnaazsold
- Saxonov Sergesold
- Saxonov Sergesold
- Saxonov Sergesold
35 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TXG.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.